Hyphens Pharma's Q3 Net Profit Falls to $2m
Hyphens Pharma's Q3 Net Profit Falls to $2m
Revenue rose 2.5% year-on-year from $42.8m to $43.9m, driven by stronger sales in Singapore and Malaysia. Meanwhile, revenue rose thanks to stronger sales in Singapore and Malaysia.
同時，由於新加坡和馬來西亞的銷售強勁，收入增長。
Hyphens Pharma International Limited's net profit for the third quarter fell by 5.6% to $2m, down from $2.1m in the same period last year, its bourse filing showed.
Hyphens Pharma International Limited的證券交易所文件顯示，其第三季度的淨利潤從去年同期的210萬美元下降了5.6％，至200萬美元。
The group attributed the decline to higher distribution and manpower costs and increased administrative expenses. This was partially offset by a higher gross profit and exchange gains from favourable currency movements against the US dollar and euro.
該集團將下降歸因於分配和人力成本的增加以及管理開支的增加。由於貨幣兌美元和歐元的有利波動，毛利潤和匯兌收益的增加部分抵消了這一點。
Revenue rose 2.5% year-on-year from $42.8m to $43.9m, driven by stronger sales in Singapore and Malaysia.
受新加坡和馬來西亞銷售強勁的推動，收入同比增長2.5％，從4,280萬美元增至4,390萬美元。
September revenue increased by 22.1% to $143.5m, mainly due to growth in the specialty pharma principals segment, including new sales from distributorships with Laboratoires Gilbert S.A.S and higher demand for its medical aesthetics range.
9月份收入增長了22.1％，達到1.435億美元，這主要是由於特種藥品主要業務板塊的增長，包括與Laboratoires Gilbert S.A.S的分銷業務的新銷售額以及對其醫學美容系列的需求增加。
Revenue from the proprietary brands segment grew by 16.9%, whilst the medical hypermart and digital segments posted a 3% increase.
專有品牌板塊的收入增長了16.9％，而醫療超市和數字板塊的收入增長了3％。
